Earticle

현재 위치 Home

Original Article

혈액종양 입원 환자 대상 임상약사의 처방중재활동 및 회피비용 분석
Cost Avoidance and Clinical Pharmacist Interventions on Hospitalized Patients in Hematologic malignancies

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 KCI 등재 바로가기
  • 통권
    제32권 제3호 (2022.09)바로가기
  • 페이지
    pp.215-225
  • 저자
    김예슬, 홍소연, 김윤희, 최경숙, 이정화, 이주연, 김은경
  • 언어
    한국어(KOR)
  • URL
    https://www.earticle.net/Article/A418384

※ 기관로그인 시 무료 이용이 가능합니다.

4,200원

원문정보

초록

영어
Background: Patients with hematologic cancers have a risk of drug-related problems (DRPs) from medications associated with chemotherapy and supportive care. Although the role of oncology pharmacists has been widely documented in the literature, few studies have reported its impact on cost reduction. This study aimed to describe the activities of oncology pharmacists with respect to hematologic diseases and evaluate the associated cost avoidance. Methods: From January to July 2021, patients admitted to the department of hemato-oncology at Seoul National University, Bundang Hospital were studied. The activities of oncology pharmacists were reported by DRP type following the Pharmaceutical Care Network version 9.1 guidelines, and the acceptance rate was calculated. The avoided cost was estimated based on the cost of the pharmacy intervention, pharmacist manpower, and prescriptions associated with the intervention. Results: Pharmacists intervened in 584 prescriptions from 208 patients during the study period. The most prevalent DRP was “adverse drug event (possibly) occurring” (32.4%), followed by “effect of drug treatment not optimal” (28.6%). “Drug selection” (42.5%) and “dose selection” (30.3%) were the most common causes of DRPs. The acceptance rate of the interventions was 97.1%. The total avoidance cost was KRW 149,468,321; the net profit of the avoidance cost, excluding labor costs, was KRW 121,051,690; and the estimated cost saving was KRW 37,223,748. Conclusion: Oncology pharmacists identified and resolved various types of DRPs from prescriptions for patients with hematologic disease, by reviewing the prescriptions. Their clinical service contributed to enhanced patient safety and the avoidance of associated costs.

목차

ABSTRACT
연구 방법
연구 대상 및 기간
자료 수집 방법 및 항목
피험자 보호
분석 방법
연구 결과
연구 대상자 특성
처방중재활동 분석
회피비용 분석
고찰
결론
이해상충
참고문헌

저자

  • 김예슬 [ Ye Seul Kim | 분당서울대학교병원 약제부 ] First Auther
  • 홍소연 [ So Yeon Hong | 분당서울대학교병원 약제부 ] First Auther
  • 김윤희 [ Yoon Hee Kim | 분당서울대학교병원 약제부 ]
  • 최경숙 [ Kyung Suk Choi | 분당서울대학교병원 약제부 ]
  • 이정화 [ Jeong Hwa Lee | 분당서울대학교병원 약제부 ]
  • 이주연 [ Ju-Yeun Lee | 서울대학교 약학대학 ]
  • 김은경 [ Euni Lee | 서울대학교 약학대학 ] Corresponding Author

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제32권 제3호

    피인용수 : 0(자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      페이지 저장